Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2012 Apr 13;11(7):1565–1575. doi: 10.1158/1535-7163.MCT-11-0938

Figure 3. Enhancement of the glucocorticoid response by combination treatment with PF-03084014 and dexamethasone.

Figure 3

(A) Heat map representation of top differentially expressed genes associated with PF-03084014 plus dexamethasone compared with dexamethasone treatment alone. Relative expression levels are color-coded as indicated at the bottom. (B) Quantitative RT-PCR analysis of HES1, DTX1, NR3C1, and BCL2L11 genes in CUTLL1 cells treated with DMSO, PF-03084014, dexamethasone, or PF-03084014 plus dexamethasone. Data are represented relative to DMSO-treated cells. *** indicates a P value < 0.001. (C) Western blot analysis of NR3C1 protein levels following 24 hours treatment of the CUTLL1 cell line with DMSO, 1µM PF-03084014, 1µM dexamethasone, or PF-03084014 plus dexamethasone; β-Actin is shown as a loading control.